Key terms
About ALT
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ALT news
Yesterday
9:00pm ET
Class Action Filed Against Altimmune, Inc. (ALT) Seeking Recovery for Investors – Contact Levi & Korsinsky LLP
May 02
11:10am ET
Biotech Alert: Searches spiking for these stocks today
May 01
10:51am ET
Biotech Alert: Searches spiking for these stocks today
May 01
10:25am ET
Altimmune call volume above normal and directionally bullish
Apr 30
11:05am ET
Altimmune call volume above normal and directionally bullish
Apr 29
7:14am ET
Altimmune downgraded to Neutral at Guggenheim on pemvidutide’s uncertain future
Apr 29
6:28am ET
Altimmune downgraded to Neutral from Buy at Guggenheim
Apr 03
8:11am ET
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Terns Pharmaceuticals (TERN) and Altimmune (ALT)
Apr 01
12:15pm ET
Altimmune’s Pemvidutide Shows Promise for Obesity Treatment, Justifying Buy Rating
Apr 01
12:00pm ET
Altimmune price target lowered to $12 from $15 at H.C. Wainwright
Mar 28
9:05am ET
Altimmune has ‘ideal lifestyle anti-obesity drug,’ says B. Riley
Mar 28
8:00am ET
Analysts Are Bullish on Top Healthcare Stocks: Moderna (MRNA), Altimmune (ALT)
Mar 28
7:30am ET
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Kiora Pharmaceuticals (KPRX) and Actinium Pharmaceuticals (ATNM)
Mar 27
5:25pm ET
Buy Rating Affirmed for Altimmune as Pemvidutide Shows Promising Weight Loss and Lean Mass Preservation
Mar 27
3:40pm ET
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Altimmune (ALT)
Mar 27
3:35pm ET
Piper continues to be bullish on Altimmune
Mar 27
9:41am ET
Unusually active option classes on open March 27th
Mar 27
7:09am ET
Altimmune reports Q4 EPS (54c), consensus (43c)
Mar 25
8:00am ET
Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024
Mar 05
9:39am ET
Altimmune Stock (NASDAQ:ALT) Rides Volatility Wave Despite Promising Pipeline
Feb 29
10:57am ET
Biotech Alert: Searches spiking for these stocks today
Feb 29
10:57am ET
Biotech Alert: Searches spiking for these stocks today
Feb 28
11:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 28
11:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 27
11:25am ET
Altimmune call volume above normal and directionally bullish
Feb 26
2:45pm ET
Altimmune’s Pemvidutide Poised for Market Success: A Buy Rating with a $25 Price Target
Feb 26
10:16am ET
Madrigal Pharmaceuticals downgraded to Sell at B. Riley after competitor data
Feb 26
9:40am ET
Analysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT)
Feb 26
9:40am ET
Unusually active option classes on open February 26th
Feb 15
8:55am ET
Altimmune (ALT) Gets a Buy from Piper Sandler
Feb 13
10:35pm ET
Buy Rating for Altimmune Backed by Pemvidutide’s Promise and Market Potential
Yesterday
9:15pm ET
Shareholders that lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action - ALT
Yesterday
6:11pm ET
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ALT Financials
Key terms
Ad Feedback
ALT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ALT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range